Near-infrared fluorescence-guided resection of micrometastases derived from esophageal squamous cell carcinoma using a c-Met-targeted probe in a preclinical xenograft model.

J Control Release

Center for Interventional Medicine, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China; Guangdong Provincial Key Laboratory of Biomedical Imaging and Guangdong Provincial Engineering Research Center of Molecular Imaging, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, Guangdong Province 519000, China. Electronic address:

Published: April 2021

The postoperative survival of esophageal squamous cell carcinoma (eSCC) is notably hindered by cancer recurrence due to difficulty in identifying occult metastases. Cellular mesenchymal-epithelial transition factor (c-Met), which is highly expressed in different cancers, including eSCC, has become a target for the development of imaging probes and therapeutic antibodies. In this study, we synthesized an optical probe (SHRmAb-IR800) containing a near-infrared fluorescence (NIRF) dye and c-Met antibody, which may help in NIRF-guided resection of micrometastases derived from eSCC. Cellular uptake of SHRmAb-IR800 was assessed by flow cytometry and confocal microscopy. In vivo accumulation of SHRmAb-IR800 and the potential application of NIRF-guided surgery were evaluated in eSCC xenograft tumor models. c-Met expression in human eSCC samples and lymph node metastases (LNMs) was analyzed via immunohistochemistry (IHC). Cellular accumulation of SHRmAb-IR800 was higher in c-Met-positive EC109 eSCC cells than in c-Met-negative A2780 cells. Infusion of SHRmAb-IR800 produced higher fluorescence intensity and a higher tumor-to-background ratio (TBR) than the control probe in EC109 subcutaneous tumors (P < 0.05). The TBRs of orthotopic EC109 tumors and LNMs were 3.01 ± 0.17 and 2.77 ± 0.56, respectively. The sensitivity and specificity of NIRF-guided resection of metastases derived from orthotopic cancers were 92.00% and 89.74%, respectively. IHC results demonstrated positive staining in 97.64% (124/127) of eSCC samples and 91.67% (55/60) of LNMs. Notably, increased c-Met expression was observed in LNMs compared to normal lymph nodes (P < 0.0001). Taken together, the results of this study indicated that SHRmAb-IR800 facilitated the resection of micrometastases of eSCC in the xenograft tumor model. This c-Met-targeted probe possesses translational potential in NIRF-guided surgery due to the high positive rate of c-Met protein in human eSCCs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jconrel.2021.02.019DOI Listing

Publication Analysis

Top Keywords

resection micrometastases
8
micrometastases derived
8
esophageal squamous
8
squamous cell
8
cell carcinoma
8
accumulation shrmab-ir800
8
escc
6
shrmab-ir800
5
near-infrared fluorescence-guided
4
fluorescence-guided resection
4

Similar Publications

The effect of the type of anaesthesia on long-term outcomes after cancer resection surgery: a narrative review.

Anaesthesia

February 2025

EuroPeriscope, ESA-IC Onco-Anaesthesiology Research Group ESA_IC_RG_EP, Brussels, Belgium.

Background: The peri-operative period may create a biological environment conducive to cancer cell survival and dissemination. Microscopic residual tumours (micrometastases) can be dislodged even with excellent surgical technique. At the same time, the stress response from surgery can temporarily impair immune function and activate inflammatory processes, increasing the risk of tumour proliferation.

View Article and Find Full Text PDF

Advances in pharmacotherapy for the treatment of peritoneal metastases from colorectal cancer.

Expert Opin Pharmacother

January 2025

Department of Oncology, University of Alberta, Cross Cancer Institute, Edmonton, Alberta, Canada.

Article Synopsis
  • Patients with peritoneal metastasis from colorectal cancer have a poor prognosis, but cytoreductive surgery is a key treatment to remove large tumors, though micrometastases often remain.
  • Systemic chemotherapy is a standard treatment for these micrometastases, but intraperitoneal therapy can deliver higher doses directly to the affected area while reducing side effects.
  • The review suggests more research is needed to establish the effectiveness of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with surgery, and explores emerging therapies like oncolytic viruses and small-molecule inhibitors for treating peritoneal metastasis.
View Article and Find Full Text PDF

[Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer].

Korean J Gastroenterol

September 2024

Division of Gastroenterology, Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea.

Surgical resection of a primary tumor is the only effective curative treatment for patients with localized pancreatic cancer without a distant metastasis. Nevertheless, most patients eventually develop postoperative recurrence caused by micrometastases. The risk increases if a complete resection is not achieved.

View Article and Find Full Text PDF

25 to 50% of patients suffering from colorectal cancer develop liver metastases. The incidence of regional lymph node (LN) metastases within the liver is up to 14%. The need for perihilar lymph node dissection (LND) is still a controversial topic in patients with colorectal liver metastases (CRLM).

View Article and Find Full Text PDF

Increasing monocytes after lung cancer surgery triggers the outgrowth of distant metastases, causing recurrence.

Cancer Immunol Immunother

September 2024

Division of General Thoracic Surgery, Department of Surgery, Shiga University of Medical Science, Tsukinowacho, Seta, Otsu City, Shiga, 520-2192, Japan.

Patients with lung cancer have a high incidence of tumor recurrence even after curative surgical resection. Some reports indicated that immunosuppressive cells induced by surgical stress could contribute to tumor recurrence after surgery; however, the underlying mechanisms are not fully understood. In this study, we found that increased postoperative blood monocytes served as a risk factor for tumor recurrence in 192 patients with non-small cell lung cancer (NSCLC).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!